The mission of Insulet Corporation is to improve the lives of people with diabetes. Through its revolutionary OmniPod Insulin Management System, Insulet seeks to expand the use of pump therapy throughout the world.


The OmniPod System was initially launched in the United States in 2005. Availability expanded with the launch of OmniPod into Latin America and Israel. In January, 2010, Insulet signed an international distribution agreement for the OmniPod System with Ypsomed AG, a leading independent diabetes specialist and technology provider.


In July, 2010, Ypsomed began distributing the OmniPod Insulin Management System in a number of countries outside the United States, primarily focused on Europe. Visit for additional information on product availability or contact your local Ypsomed division.


Ypsomed AG
Brunnmattstrasse 6
3401 Burgdorf / Switzerland
Phone: +41 (0)34 424 41 11
Fax: +41 (0)34 424 41 22


In March, 2011, Insulet signed an exclusive distribution agreement with GlaxoSmithKline, Inc. (GSK), one of the world's leading research-based pharmaceutical and healthcare companies. In September, 2011, GSK began distributing the OmniPod System in Canada. Visit for additional information on product availability.


GlaxoSmithKline Inc.
7333 Mississauga Rd.
Mississauga, Ontario
L5N 6L4
Phone: 1-855-POD-INFO (1-855-763-4636)


To get the all the latest information about the OmniPod System, please join our e-mail newsletter PodWatch.